Generic copies of the two best-selling drugs, Lipitor and Plavix, will reach pharmacy shelves this year, providing less-expensive alternatives to lowering cholesterol and preventing blood clots.
The drugs are among six blockbusters that will lose patent protection this year. The others are Levaquin, an antibiotic; Taxotere, a cancer drug; Concerta, for attention deficit hyperactivity disorder; and Zyprexa, for treatment of schizophrenia.
Lipitor and Plavix account for $13.1 billion in combined annual sales.
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
The availability of generic equivalents will help users and employers save money. In 2009, the average retail price was 75% lower than the price of name-brand drugs. In addition to the lower cost, many prescription drug plans require lower copays for generics than for brand-name medications.
Generic drugs claimed about 75% of the market in 2009. The share is expected to reach 85% by 2014.
Despite generic availability of some monster drugs, you should expect a 5% increase in overall drug costs in 2011, the third straight year of single-digit increases. Part of the reason is that generics will be phased in. The Lipitor equivalent, for example, won’t be available until late fall.
The generics shouldn’t have much impact on drug company stock prices when they hit the market. The coming end of patent protection has been known well in advance, so any adjustment is likely already factored into share prices.
-
Stock Market Today: Dow Adds 654 Points as 3M Stock Explodes HigherIt was a risk-on day for stocks thanks to an upbeat inflation reading and impressive earnings from 3M and Deckers.
-
3M Leads Dow Stocks After Massive Earnings Beat3M stock is headed toward its best day ever after the industrial conglomerate's impressive earnings report. Here's what you need to know.
-
Astronomical AI Spending Is Causing Jitters on Wall StreetThe Kiplinger Letter Amid rampant excitement over artificial intelligence, a new round of skepticism is taking hold. Here are four forecasts about the future of generative AI.
-
Car Prices Are Finally Coming DownThe Kiplinger Letter For the first time in years, it may be possible to snag a good deal on a new car.
-
Rising Cyber Threat of AI: The Kiplinger LetterThe Kiplinger Letter Security experts warn that generative AI brings new risks with no clear defenses. With AI's rapid adoption, businesses are vulnerable.
-
Kiplinger Special: The Long-Term Future of the U.S. EconomyThe Kiplinger Letter Kiplinger's report into what it will take the U.S. to maintain a healthy economic growth rate.
-
The Fight Against Cancer Enters a New PhaseThe Kiplinger Letter Breakthrough treatments hold promise for patients and investors.
-
After Decades of Promise, the Virtual Reality Era Has Finally ArrivedThe Kiplinger Letter VR is a paradigm shift for consumer technology. The tech has a long road ahead, but amazing hardware already puts the huge potential on full display.
-
AI to Power the Next Generation of RobotsThe Kiplinger Letter There's increasing buzz that the tech behind ChatGPT will make future industrial and humanoid robots far more capable.
-
The Robots Are Coming... But Not For a While
The Kiplinger Letter There’s excitement in the tech sector over the potential of humanoid robots, but widespread adoption is likely to be years away.
